Welcome to our dedicated page for Petvivo Hldgs news (Ticker: PETV), a resource for investors and traders seeking the latest updates and insights on Petvivo Hldgs stock.
PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) generates news across animal health, regenerative medicine and veterinary-focused artificial intelligence. The company, together with its subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc., reports on developments in its veterinary medical devices, platelet-rich plasma products and AI platforms designed for companion animals and horses.
News coverage for PetVivo often highlights updates on its lead products SPRYNG® with OsteoCushion® technology and PrecisePRP®, including distribution agreements, clinical adoption by veterinary practices and educational initiatives such as continuing education courses and conference presentations. Press releases also describe how these products are promoted through vendor partnerships and distributor networks, as well as their use in managing osteoarthritis, lameness and other joint-related conditions in cats, dogs and horses.
Another key theme in PetVivo news is its expansion into veterinary AI and digital platforms. Announcements have detailed the launch of the PetVivo.ai platform, an AI-powered system intended to improve veterinary client acquisition and engagement through multiple specialized AI agents. Additional releases cover PetVivo’s exclusive 10-year white-label licensing agreement for the Agentic Pet AI framework, publication of a technical whitepaper validating this multi-agent architecture and plans for dual-platform launches that connect pet parents with veterinary practices.
Investors and veterinary professionals following PETV news can also see updates on strategic alliances, board appointments, investor conference presentations and financial results. Earnings-related releases describe revenue trends, product mix developments and distribution expansion, while corporate announcements provide insight into capital structure actions and governance changes. For ongoing context around PetVivo’s products, partnerships and AI initiatives, this news feed offers a centralized view of the company’s public disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
PetVivo Holdings, a biomedical device company focused on innovative therapeutics for pets, will present at the Aegis Capital Virtual Conference from May 2nd to 4th, 2023. CEO John Lai will discuss the company's Spryng product featuring OsteoCushion Technology, aimed at managing lameness and joint issues in companion animals.
Spryng is an injectable device that supports joint health by mimicking natural cartilage and is currently available for sale. The presentation is scheduled for May 3rd, 2023, from 12:25 PM to 12:55 PM ET. PetVivo holds a strong patent portfolio, with 17 products in development and a unique market strategy focused on veterinary devices.
PetVivo Holdings (NASDAQ: PETV, PETVW) has appointed Mary Grace Rutland as the new Business Development Manager for the Mid-Atlantic Region. Rutland, with 24 years of experience in animal health sales, will focus on promoting Spryng with OsteoCushion technology to veterinarians across the U.S. CEO John Lai expressed excitement about her addition, highlighting her previous roles in the industry, including positions at Fort Dodge Animal Health and Neogen Corporation. PetVivo specializes in innovative medical devices for companion animals, with Spryng aimed at treating lameness and joint-related conditions like osteoarthritis in dogs and horses. The company has a pipeline of 17 products and holds 19 patents covering its biomaterials and methods.
PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) announces its participation at the ACVSMR Symposium from April 28-29, 2023, in Charleston, South Carolina. The company will showcase its lead product, SPRYNG™ with OsteoCushion™ Technology, designed for managing joint afflictions in pets, particularly osteoarthritis. This event provides a platform for PetVivo to demonstrate its innovative veterinary medical device to experts in the field. CEO John Lai emphasized the importance of this opportunity to discuss how Spryng can enhance the quality of life for companion animals. The company’s focus is on leveraging human therapies for veterinary applications, with a pipeline containing seventeen products and a portfolio of nineteen patents.
PetVivo Holdings (NASDAQ: PETV, PETVW) has appointed Spencer Breithaupt to its Board of Directors, bringing over 30 years of experience in the animal health industry. Breithaupt, previously with MWI Animal Health and Fortune 500 companies, is expected to enhance the company's industry relationships and strategic direction. CEO John Lai expressed confidence that Breithaupt's expertise will be instrumental in advancing PetVivo’s mission. The company specializes in biomedical devices for companion animals and currently offers its lead product, SPRYNG with OsteoCushion technology, which is designed to manage joint-related afflictions in animals.
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has announced its participation as a Platinum Sponsor at the International Veterinary Academy of Pain Management (IVAPM) Pain Management Forum from April 2-4, 2023, in Atlanta, Georgia. The company will showcase its lead product, SPRYNG™ with OsteoCushion™ Technology, designed to manage lameness and joint-related issues, particularly osteoarthritis. CEO John Lai emphasizes the forum as a crucial opportunity to present the benefits of SPRYNG to veterinary pain management experts. PetVivo is focused on the commercialization of innovative medical devices for companion animals and has a pipeline of seventeen products.
FAQ
What is the current stock price of Petvivo Hldgs (PETV)?
What is the market cap of Petvivo Hldgs (PETV)?
